Cutaneous manifestations of antiretroviral therapy
Journal of the American Academy of Dermatology, ISSN: 0190-9622, Vol: 46, Issue: 2, Page: 284-293
2002
- 73Citations
- 39Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations73
- Citation Indexes73
- 73
- CrossRef61
- Captures39
- Readers39
- 39
Article Description
The pandemic created by HIV, a retrovirus, has stimulated increased research in viral diseases and has generated greater interest in the development of antiretroviral medications. These new medications are presently divided into 3 categories: protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and nucleoside reverse transcriptase inhibitors (NRTIs). These antiretroviral agents carry their own risk for causing adverse reactions, as well as drug interactions. The most recently approved class of antiretrovirals, PIs have been associated with lipodystrophy syndrome, hypersensitivity reactions, urticaria, morbilliform eruptions, and a large number of drug interactions. NNRTIs have resulted in various cutaneous eruptions, as well as a hypersensitivity syndrome. NRTIs have resulted in alterations of the nails, nail and mucocutaneous pigmentation, hair changes, vasculitis, and morbilliform eruptions. This article focuses on the cutaneous manifestations of antiretroviral therapy to help dermatologists recognize them. (J Am Acad Dermatol 2002;46:284-93.)
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0190962202192723; http://dx.doi.org/10.1067/mjd.2002.119105; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0036160486&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/11807442; https://linkinghub.elsevier.com/retrieve/pii/S0190962202192723; https://dx.doi.org/10.1067/mjd.2002.119105
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know